Faisal Masud, MD
Critical Care Medicine · Houston, TXNPI 1023054525
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,823 of the $154,819 with a category attached, or 61.9%. 13 manufacturers reported payments, led by AstraZeneca at 48.9% of the total. Reporting peaked in 2023 at $45,361 and has fallen 68.5% since, to $14,269 in 2025. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $905.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$76K
- Teleflex LLC$30K
- Gilead$24K
- BTG International Inc.$10K
- Portola Pharmaceuticals, LLC$9K
- La Jolla Pharmaceutical Company$3K
- plus $3K from 7 others
Across 10 payments — averaging $6379.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$35K
- Dompe Farmaceutici S.p.a.$29K
What the payments were for
- Consulting fees$40,50526%
- Speaking & faculty fees$95,82362%
- Travel & lodging$14,4369%
- Food & beverage$4,0563%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 81 | $75,720 |
| Teleflex LLC | 28 | $30,345 |
| Gilead | 26 | $23,929 |
| BTG International Inc. | 5 | $10,452 |
| Portola Pharmaceuticals, LLC | 15 | $8,618 |
| La Jolla Pharmaceutical Company | 4 | $2,965 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $1,258 |
| AbbVie | 1 | $1,000 |
| Merck | 2 | $231 |
| Boston Scientific | 4 | $151 |
| Melinta Therapeutics, LLC | 1 | $79 |
| Mindray DS USA, Inc. | 1 | $37 |
| Medtronic | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$82,919
- Veklury$23,555
- Arrow$19,147
- GIAPREZA$2,925
- MIDLINE (AGB-A)$2,400
- PICC - ARROW$2,000
- CVC (AGB+)$2,000
- TEFLARO$1,000
- RECARBRIO$124
- ZERBAXA$106
How this compares
$154,819 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Houston
- Edwin ParsleyHouston$283K
- Bindu AkkantiHouston$185K
- Sergio Trevino CastilloHouston$133K
- Sami HossriHouston$34K
- George WilliamsHouston$33K
- Nicholas VillalobosHouston$26K
- Ranjan UpadhyayHouston$25K
- Deepa GoturHouston$23K
- Hany Abd-El MalekHouston$19K
- Kha DinhHouston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.